Dr. Rosemary Tan is CEO of Leyden Labs Asia, a subsidiary of Leyden Laboratories B.V., which develops intranasal antibody therapies for broad protection against respiratory viruses. Prior to this, she led CoV Biotechnology, focused on coronavirus vaccines and antibodies, which was acquired by Leyden Labs in 2024. Earlier in her career, she founded Veredus Laboratories, a pioneer in diagnostic and bio-surveillance technologies which was acquired by Sekisui Chemical.

Dr Tan received her PhD from the National University of Singapore, with research conducted at the University of Tokyo. As a leader in Singapore’s life sciences sector, she serves on national committees including SGInnovate, National University of Singapore iHealthtech and National University Health System Practice Change Innovation Committee. Her career is a testament to her unwavering commitment to scientific innovation, leadership, and global health, shaping the future of biotechnology and pandemic preparedness.